Cargando…
Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
The death rate from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in 2022 was lower than the death rate in 2021, when the infection rate increased. Hybrid immunity provided by a combination of vaccination and infection, including asymptomatic infection, may confer effective...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840162/ https://www.ncbi.nlm.nih.gov/pubmed/36641523 http://dx.doi.org/10.1038/s41598-023-28101-5 |
_version_ | 1784869583880978432 |
---|---|
author | Chevaisrakul, Parawee Lumjiaktase, Putthapoom Kietdumrongwong, Pongtorn Chuatrisorn, Ittiporn Chatsangjaroen, Pongsan Phanuphak, Nittaya |
author_facet | Chevaisrakul, Parawee Lumjiaktase, Putthapoom Kietdumrongwong, Pongtorn Chuatrisorn, Ittiporn Chatsangjaroen, Pongsan Phanuphak, Nittaya |
author_sort | Chevaisrakul, Parawee |
collection | PubMed |
description | The death rate from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in 2022 was lower than the death rate in 2021, when the infection rate increased. Hybrid immunity provided by a combination of vaccination and infection, including asymptomatic infection, may confer effective protection against death. We explored the combined effect of asymptomatic infection and hybrid immunity by studying T-cell and antibody responses against SARS-CoV-2 among individuals treated in home health care services 6 months after SARS-CoV-2 exposure. Asymptomatic SARS-CoV-2 infection was demonstrated in 24.4% of close contacts. The levels of immunity were not different between patients and close contacts. Anti-RBD IgG against SARS-CoV-2 increased in a dose-dependent manner with the number of vaccine doses. Interestingly, the T-cell response decreased soon after a booster dose of vaccine. Asymptomatic SARS-CoV-2 infection could not enhance immunity against SARS-CoV-2 among vaccinated close contacts. Full vaccination was crucial to provide hybrid immunity. However, when designing vaccine strategies, T-cell exhaustion after multiple vaccinations should be considered. |
format | Online Article Text |
id | pubmed-9840162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98401622023-01-16 Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program Chevaisrakul, Parawee Lumjiaktase, Putthapoom Kietdumrongwong, Pongtorn Chuatrisorn, Ittiporn Chatsangjaroen, Pongsan Phanuphak, Nittaya Sci Rep Article The death rate from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in 2022 was lower than the death rate in 2021, when the infection rate increased. Hybrid immunity provided by a combination of vaccination and infection, including asymptomatic infection, may confer effective protection against death. We explored the combined effect of asymptomatic infection and hybrid immunity by studying T-cell and antibody responses against SARS-CoV-2 among individuals treated in home health care services 6 months after SARS-CoV-2 exposure. Asymptomatic SARS-CoV-2 infection was demonstrated in 24.4% of close contacts. The levels of immunity were not different between patients and close contacts. Anti-RBD IgG against SARS-CoV-2 increased in a dose-dependent manner with the number of vaccine doses. Interestingly, the T-cell response decreased soon after a booster dose of vaccine. Asymptomatic SARS-CoV-2 infection could not enhance immunity against SARS-CoV-2 among vaccinated close contacts. Full vaccination was crucial to provide hybrid immunity. However, when designing vaccine strategies, T-cell exhaustion after multiple vaccinations should be considered. Nature Publishing Group UK 2023-01-14 /pmc/articles/PMC9840162/ /pubmed/36641523 http://dx.doi.org/10.1038/s41598-023-28101-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Chevaisrakul, Parawee Lumjiaktase, Putthapoom Kietdumrongwong, Pongtorn Chuatrisorn, Ittiporn Chatsangjaroen, Pongsan Phanuphak, Nittaya Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program |
title | Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program |
title_full | Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program |
title_fullStr | Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program |
title_full_unstemmed | Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program |
title_short | Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program |
title_sort | hybrid and herd immunity 6 months after sars-cov-2 exposure among individuals from a community treatment program |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840162/ https://www.ncbi.nlm.nih.gov/pubmed/36641523 http://dx.doi.org/10.1038/s41598-023-28101-5 |
work_keys_str_mv | AT chevaisrakulparawee hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram AT lumjiaktaseputthapoom hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram AT kietdumrongwongpongtorn hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram AT chuatrisornittiporn hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram AT chatsangjaroenpongsan hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram AT phanuphaknittaya hybridandherdimmunity6monthsaftersarscov2exposureamongindividualsfromacommunitytreatmentprogram |